Skip to main content

NGM to Host Virtual R&D Day on December 9, 2020

Written by Customer Service on . Posted in Public Companies.

– Event to showcase NGM’s multi-therapeutic area pipeline, including its oncology portfolio and Geographic Atrophy and NASH programs – 
– Planned presentations from NGM management, NGM scientists and leading industry physicians –– Fireside chat with executives from Merck Research Laboratories –SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) —  NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host a virtual R&D Day on December 9, 2020 at 12:00 pm ET.The R&D Day will highlight NGM’s productive, 100+ researcher-led discovery engine and feature NGM’s pipeline of drug candidates in liver and metabolic diseases (aldafermin and MK-3655), retinal disease (NGM621) and cancer (NGM120 and NGM707). NGM also plans to unveil an additional oncology candidate at the event.Members of NGM’s management and senior NGM scientists will present the company’s pipeline of programs and the unmet patient needs each aims to address. Guest speakers will include:Daniel Von Hoff, M.D., F.A.C.P., Distinguished Professor, The Translational Genomics Research InstituteArun Sanyal, M.D., Professor, Internal Medicine, Virginia Commonwealth UniversityRobert Schreiber, Ph.D., Distinguished Professor, Pathology & Immunology, Washington University School of MedicineCharles Wykoff, M.D., Ph.D., Director of Research at Retina Consultants HoustonAs part of the event, NGM will host a fireside chat with Roger M. Perlmutter, M.D., Ph.D., President, Merck Research Laboratories, and Dean Y. Li, M.D., Ph.D., Senior Vice President of Discovery Sciences and Translational Medicine, Merck Research Laboratories, to discuss the collaboration between NGM and Merck. The two companies have an ongoing broad, multi-year strategic collaboration to discover, develop and commercialize novel therapies across a wide range of therapeutic areas.A live webcast of the event will be available at ir.ngmbio.com under ‘Events & Presentations’. A replay of the webcast will be archived on the NGM website for one year following the presentation.To register for the NGM R&D Day, please sign up here.About NGM Biopharmaceuticals, Inc.NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit us at www.ngmbio.com for more information.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.